Neurocrine Biosciences Shares Rise After FDA Approves CRENESSITY

Shares of Neurocrine (NASDAQ:NBIX) climbed 5.7% following the U.S. Food and Drug Administration’s approval of CRENESSITY, a new treatment for congenital adrenal hyperplasia (CAH). CRENESSITY is the first medication to directly target and reduce excess adrenocorticotropic hormone (ACTH) and adrenal androgen production in patients suffering from this genetic disorder.

The FDA's approval, announced on a Friday, marks a significant advancement for those affected by classic CAH, a rare and lifelong condition impacting the adrenal glands. The medication is expected to become commercially available within a week through PANTHERx Rare, a specialized pharmacy service.

Kyle W. Gano, Ph.D., CEO of Neurocrine Biosciences, emphasized the company's dedication to CAH research and expressed gratitude to clinical trial participants and investigators for their contributions in introducing this new medicine to the CAH community. Dina Matos, Executive Director of the CARES Foundation, also recognized the drug's potential to enhance the quality of life for CAH patients by minimizing high-dose steroid treatment needs.

Despite this positive reception, analysts predict a gradual commercial rollout. Evan David Seigerman of BMO Capital highlighted challenges, indicating that broad commercial access may not be anticipated until the second half of 2025. Additionally, the drug carries a black box warning necessitating careful supervision of glucocorticoid therapy adjustments.

Chris Shibutani from Goldman Sachs noted the approval as a significant milestone for Neurocrine Biosciences, establishing its reputation among biotech firms adept at developing multiple drugs across various therapeutic areas. He added that while the initial launch trajectory is hard to estimate, the company’s advancement will be monitored concerning patient capture and insurance coverage expansion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.